Compare QMCO & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMCO | KRRO |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.1M | 150.0M |
| IPO Year | 2025 | 2019 |
| Metric | QMCO | KRRO |
|---|---|---|
| Price | $13.71 | $14.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $10.50 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 1.6M | 175.0K |
| Earning Date | 02-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $372,827,000.00 | $6,392,000.00 |
| Revenue This Year | $0.32 | N/A |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.65 | ★ 181.46 |
| 52 Week Low | $4.19 | $5.20 |
| 52 Week High | $18.48 | $55.89 |
| Indicator | QMCO | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 63.11 |
| Support Level | $5.93 | $10.02 |
| Resistance Level | $15.33 | $14.42 |
| Average True Range (ATR) | 2.36 | 1.08 |
| MACD | -0.04 | 0.34 |
| Stochastic Oscillator | 28.97 | 85.61 |
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.